Management of Acute COPD Exacerbations

Corticosteroid Dosing Protocol

The American Thoracic Society and European Respiratory Society recommend prednisone 30-40 mg orally once daily for 5 days as the evidence-based standard for acute COPD exacerbations, with a strength of evidence rated as high 1, 2, 3
A 5-day course of corticosteroids is as effective as longer durations (10-14 days) in improving lung function and symptoms, while minimizing adverse effects, with a moderate strength of evidence 2
Oral prednisone is preferred over intravenous administration, with a high strength of evidence, as it is equally effective for clinical outcomes and reduces the risk of adverse effects 2, 3
The use of corticosteroids shortens recovery time, improves lung function, reduces treatment failure rates, and may decrease hospital length of stay, with a high strength of evidence 1, 2
Blood eosinophil count ≥2% predicts better response to corticosteroids, with a moderate strength of evidence, but treatment should not be withheld based on eosinophil levels alone 2

The American College of Chest Physicians recommends giving antibiotics when patients have increased sputum purulence plus either increased dyspnea or increased sputum volume, with a high strength of evidence 3, 4
The recommended duration of antibiotic therapy is 5-7 days, with a high strength of evidence, and first-line options include amoxicillin-clavulanate, doxycycline, and trimethoprim-sulfamethoxazole 1, 3, 4
Antibiotics reduce short-term mortality, treatment failure, and sputum purulence, with a high strength of evidence, but should be reserved for patients meeting specific criteria to minimize unnecessary use 3, 1
The choice of antibiotic should be based on local bacterial resistance patterns, with a moderate strength of evidence 3

For ambulatory or mild exacerbations, treatment with short-acting bronchodilators, prednisone 40 mg daily for 5 days, and antibiotics (if indicated) is recommended, with a high strength of evidence 3, 4, 2
For moderate exacerbations, treatment with short-acting bronchodilators via nebulizer or MDI, prednisone 40 mg daily for 5 days, and antibiotics (if indicated) is recommended, with a high strength of evidence 3, 4, 2
For severe or hospitalized exacerbations, treatment with nebulized short-acting β2-agonists, prednisone 40 mg daily for 5 days (or IV hydrocortisone 100 mg if unable to take oral), and antibiotics is recommended, with a high strength of evidence 3, 4, 2

Do not prescribe prednisone doses >200 mg total (prednisone equivalents) for the exacerbation course, as higher doses show no benefit and increase adverse effects, with a moderate strength of evidence 2
Do not extend corticosteroid treatment beyond 5-7 days, as this increases risks without improving outcomes, with a high strength of evidence 2
Do not give antibiotics to all patients reflexively, but rather reserve for those meeting purulent sputum criteria, with a high strength of evidence 1, 3
Do not use IV corticosteroids routinely, as oral administration is equally effective and preferred, with a high strength of evidence 2, 3
Do not use methylxanthines (theophylline), as they have increased side effect profiles without added benefit, with a moderate strength of evidence 2, 3

Avoid prolonged systemic corticosteroid therapy beyond the first 30 days after an acute COPD exacerbation – a Grade 1A recommendation indicating strong, high‑quality evidence that long‑term use does not prevent further exacerbations and increases harm. 5

Hyperglycemia risk is markedly increased (odds ratio ≈ 2.8) in patients receiving a short course of systemic corticosteroids for COPD exacerbations; close blood‑glucose monitoring is advised, especially in individuals with diabetes. 5
Short‑term corticosteroid exposure is associated with weight gain and insomnia, while extended use adds risks of infection, osteoporosis, and adrenal suppression; these adverse effects underscore the importance of limiting therapy to ≤5–7 days. 5